Armistice Capital LLC Trims Position in Vaccinex, Inc. (NASDAQ:VCNX)

Armistice Capital LLC reduced its holdings in Vaccinex, Inc. (NASDAQ:VCNX) by 35.2% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 94,000 shares of the company’s stock after selling 51,000 shares during the period. Armistice Capital LLC owned about 5.93% of Vaccinex worth $610,000 at the end of the most recent quarter.

Separately, AIGH Capital Management LLC lifted its position in Vaccinex by 86.7% during the second quarter. AIGH Capital Management LLC now owns 108,958 shares of the company’s stock valued at $707,000 after purchasing an additional 50,593 shares during the period. 50.11% of the stock is currently owned by institutional investors.

Vaccinex Stock Performance

NASDAQ:VCNX opened at $3.27 on Friday. The firm’s fifty day moving average is $5.45 and its two-hundred day moving average is $6.11. The firm has a market cap of $5.66 million, a price-to-earnings ratio of -0.04 and a beta of 0.99. Vaccinex, Inc. has a one year low of $3.20 and a one year high of $28.56.

Vaccinex (NASDAQ:VCNX) last posted its earnings results on Wednesday, August 14th. The company reported ($3.10) EPS for the quarter. The company had revenue of $0.23 million during the quarter.

Insider Transactions at Vaccinex

In other news, Director Albert Friedberg bought 200,000 shares of the firm’s stock in a transaction that occurred on Wednesday, July 31st. The stock was purchased at an average cost of $6.15 per share, for a total transaction of $1,230,000.00. Following the purchase, the director now directly owns 762,415 shares in the company, valued at approximately $4,688,852.25. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders have bought 203,753 shares of company stock valued at $1,247,255 in the last 90 days. 51.50% of the stock is currently owned by company insiders.

About Vaccinex

Vaccinex, Inc, a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D.